Bone turnover forecasts prostate cancer outcomes

According to a study published in the Journal of the National Cancer Institute states that the biomarkers into bone formation and restoration predict that it may result into castration resistant prostate cancer. The markers have discovered a small group of patients who actually responded to this investigational drug atrasentan. It is predicted that this research could help the clinicians to match treatments with the individual patients for tracking their effectiveness and affect clinical trial. This is a step-ahead discovery in scientific field. It could help control the prostate cancer in a big way. The lead author Primo Lara, associate director for translational research at the UC Davis Comprehensive Cancer Center explains, “We found that patients with high levels of these markers in the blood had a much shorter lifespan compared to patients with low levels. By measuring bone turnover in prostate cancer patients, we can determine how well they do.”